The Top 3 Companies Set to Dominate US Biosimilar Market

biosimilars amgen hospira sandoz companies (hokkey Yuma Hori)

Biosimilars – products that are "highly similar" to an already-approved biological product – are on the rise in the US, although the country still lags behind other nations in the biosimilar space.  A new report from Thomson Reuters, ‘An Outlook on US Biosimilar Competition', has identified these three pharmaceutical companies as being among those that have the greatest potential to dominate the early stages of biosimilar entrances into the US:


  • At an investor meeting in February 2013, Amgen reportedly outlined plans to launch 6 new biosimilars: 4 drugs for cancer and 2 for inflammatory disease, beginning in 2017. The portfolio will include biosimilar versions of Avastin, Herceptin, Rituxan and Erbitux (Reuters).


  • Hospira's first biosimilar was Retacrit, a recombinant human erythropoietin ("EPO biosimilar") launched in Europe in 2008
  • The company's second biosimilar was Nivestim, a granulocyte colony-stimulating factor (G-CSF) analog and a filgrastim biosimilar, which was launched in Europe in 2010
  • Hospira is currently conducting a Phase III US clinical trial program with its biosimilar version of EPO (Yahoo)
  • Hospira's biosimilars pipeline, including products it shares with Celltrion, includes 11 products (Yahoo)


  • Sandoz is the generic pharmaceuticals division of Novartis
  • In October 2012, Sandoz started a Phase III trial for its biosimilar epoetin alfa in the US, with the company continuing to enroll patients for ongoing Phase II and III trials for rituximab and Phase III trials with filgrastim and pegfilgrastim (press release)
  • As March 2013, the company's biosimilar version of rituximab was "on track"

Read the press release from Thomson Reuters. What do you think? What other pharmaceutical companies do you think we should look out for in the biosimilar space? Why not join our discussion on LinkedIn, or leave a comment below.

If you want to know more about biosimilars (and particularly mAb biosimilars) you might be interested in attending the World Biosimilar Congress 2013.  Or if you're interested in antibodies, this event is also co-located with the European Antibody Congress 2013.Both these events are taking place in Geneva this November.

Want more from Total BioPharma? Sign up to our newsletter – it doesn't cost anything and only takes a minute.

Read more about biosimilars:

Global biosimilar market will grow to $2.44bn this year, says report

Biologic best-sellers and their biosimilars to keep an eye on